Mavenclad Will Be Another Oral Option to Help Treat Multiple Sclerosis

March 2018

You'll start hearing about a new oral med, Mavenclad (MAY-ven-clad, cladribine) for treating multiple sclerosis (MS).

It helps decrease the frequency of multiple sclerosis "flare-ups"...and helps delay progression of disability.

But expect Mavenclad to be saved for patients who cannot tolerate or who have had a relapse while on other MS treatments.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Poison Prevention Use National Poison Prevention Week as a Chance to Raise Awareness
Patient Privacy/HIPAA Remember "When You're Unsure, Shredding is the Cure" With Patient Information
Electrolytes Watch for Various Salt Forms of Electrolytes
Ophthalmology Think of Xiidra as an Alternative to Restasis for Dry Eye Disease
Influenza Anticipate Questions About Natural Health Products for Influenza
Vaccines Trumenba Will Join Bexsero to Help Prevent Meningitis B
Med Adherence Work as a Team to Help Patients Stick With Their Meds
Hyperglycemia Listen for Signs of High Blood Sugar in Diabetes Patients Taking a Steroid
Obesity & Weight Loss Be Prepared to Handle Med Changes After Bariatric Surgery
Multiple Sclerosis Mavenclad Will Be Another Oral Option to Help Treat Multiple Sclerosis